Cargando…
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
BACKGROUND: Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful. CASE DIAGNOSIS/TREATMENT: A female infant with massive renal enlargement, respiratory compromise and hyponatraem...
Autores principales: | Gilbert, Rodney D., Evans, Hazel, Olalekan, Kazeem, Nagra, Arvind, Haq, Mushfequr R., Griffiths, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368203/ https://www.ncbi.nlm.nih.gov/pubmed/28194574 http://dx.doi.org/10.1007/s00467-017-3584-9 |
Ejemplares similares
-
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021) -
Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018) -
Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
por: Kim, Ha Yeon, et al.
Publicado: (2018) -
Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
por: Anderegg, Manuel A., et al.
Publicado: (2020) -
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
por: Sans-Atxer, Laia, et al.
Publicado: (2018)